Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2006-02-07
2006-02-07
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C530S350000, C530S391100
Reexamination Certificate
active
06994856
ABSTRACT:
The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.
REFERENCES:
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 6727077 (2004-04-01), Young et al.
patent: 2004/0048295 (2004-03-01), Young et al.
patent: WO 92/19195 (1992-11-01), None
patent: WO 93/25673 (1993-12-01), None
patent: WO 95/05452 (1995-02-01), None
patent: WO 96/15244 (1996-05-01), None
patent: WO 96/36720 (1996-11-01), None
patent: WO 97/09425 (1997-03-01), None
Rudinger et al. in “Peptide Hormones”, edited by Parsons University Park Press, p. 6, Jun. 1976.
Burgess et al. J Cell Biol, 111:2129-2138, 1990.
Aebischer et al., “Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients”Nature Medicine(published erratum appears in Nat Med Sep. 1996; 2(9) : 1041) 2(6) :696-699 (Jun. 1996).
Barbacci et al., “The structural basis for the specificity of epidermal growth factor and heregulin binding”Journal of Biological Chemistry(published erratum appears in J Biol Chem Nov. 24, 1995;270(47) : 28494) 270(16):9585-9589 (Apr. 21, 1995).
Beerli et al., “Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities”Journal of Biological Chemistry271(11):6071-6076 (Mar. 15, 1996).
Blobel, G., “Intracellular protein topogenesis”Proc. Natl. Acad. Sci. USA77(3):1496-1500 (Mar. 1980).
Carraway et al., “The erbB3 gene product is a receptor for heregulin”Journal of Biological Chemistry269(19):14303-14306 (1994).
Carraway et al., “A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling”Cell78:5-8 (Jul. 15, 1994).
Carraway, et al., “Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases”Nature387:512-516 (1997).
Chang, et al., “Ligands for ErbB-family receptors encoded by a neuregulin-like gene”Nature387:509-512 (1997).
Derynck et al., “Human transforming growth factor-α: Precursor structure and expression inE. coli” Cell38:287-297 (1984).
Falls et al., “ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family”Cell72:801-815 (1993).
Godowski et al., “Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism”Proc. Natl. Acad. Sci. USA86:8083-8087 (1989).
Higashiyama et al., “A Heparin-Binding Growth Factor Secreted by Macrophage-Like Cells That is Related to EGF”Science251:936-939 (1991).
Hillier et al. (Genbank Database Accession No. H49100) (1995).
Ho, W., et al., “Sensory and Motor Neuron-derived Factor”Journal of Biological Chemistry270(24):14523-14532 (Jun. 16, 1995).
Holmes et al., “Identification of heregulin, a specific activator of p185erbB2”Science256:1205-1210 (1992).
Karunagaran et al., “ErbB-2 is a Common Auxiliary Subunit of NDF and EGF Receptors: Implications for Breast Cancer”EMBO Journal15(2):254-264 (1996).
Kita et al., “NDF/heregulin stimulates the phosphorylation of Her3/erb3B3”FEBS letters349(1):139-143 (Jul. 25, 1994).
Nagai et al., “Molecular cloning of cDNA cloning for human preprourokinase”Gene36(1-2):183-188 (1985).
Plowman et al., “The Amphiregulin Gene Encodes a Novel Epidermal Growth Factor-Related Protein with Tumor-Inhibitory Activity”Molecular&Cellular Biology10:1969-1981 (1990).
Plowman et al., “Heregulin induces tyrosine phosphorylation of HER4/p180erbB4”Nature(Letters to Nature) 366:473-475 (Dec. 2, 1993).
Riese et al., “The cellular response to neuregulins is governed by complex interactions of the erbB receptor family”Molecular&Cellular Biology(published erratum appears in Mol Cell Biol Feb. 1996; 16(2):735) 15(10):5770-5776 (Oct. 1995).
Sabatini et al., “Mechanisms for the incorporation of proteins in membranes and organelles”Journal of Cell Biology92(1):1-22 (Jan. 1982).
Sasada et al., “Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family”Biochemical&Biophysical Research Communications190(3):1173-1179 (Feb. 15, 1993).
Sliwkowski et al., “Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin”Journal of Biological Chemistry269(20):14661-14665 (1994).
Toyoda et al., “Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development”FEBS Letters377(3):403-407 (Dec. 27, 1995).
Tzahar et al., “ErbB-3 and ErbB-4 Function as the Respective Low and High Affinity Receptors of All Neu Differentiation Factor/Heregulin Isoforms”Journal of Biological Chemistry269(40):25226-25233 (1994).
Wickner et al., “Multiple mechanisms of protein insertion into and across membranes”Science230(4724):400-407 (Oct. 25, 1985).
Zhang et al., “Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4”Proc. Natl. Acad. Sci. USA94:9562-9567 (Sep. 22, 1997).
Mark Melanie Rose
Zhang Dong-Xiao
Canella Karen A.
Genentech, Inc.
LandOfFree
ErbB4 receptor-specific neuregulin related ligands and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ErbB4 receptor-specific neuregulin related ligands and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ErbB4 receptor-specific neuregulin related ligands and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3624605